Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of Titanium Nanoparticles on Differentially Activated Human Primary Macrophages

ABSTRACT: Long term use of titanium implants generates wearing particles off. Titanium nanoparticles (TiNP) favor a pro-inflammatory macrophage polarization (M1) and lower the tolerogenic activation (M2). Our previous Affymetrix data showed that TiNP upregulate GDF15 and downregulate STAB1 expression in macrophages. GDF15 is a cytokine that regulates energy expenditure and fibrosis, and is endocytosed by the scavenger receptor Stabilin-1. Our study aim was to investigate the effect of TiNP on GDF15 and STAB1 expression, on GDF15 secretion and on endocytosis efficiency in macrophages. We used the model system of primary human macrophages derived from CD14+ monocytes. After 6 days of incubation with TiNP, we quantified GDF15 and STAB1 expression, and GDF15 secretion in INF-γ stimulated (M1) and IL-4 stimulated (M2) macrophages using RT-PCR and ELISA, respectively. Flow cytometry assessed the effect of TiNP on endocytosis based on the uptake of fluorescently labelled acLDL, a known ligand of stabilin-1, and MS-1, an antibody directed against the extracellular portion of stabilin-1 in M1 and M2. Our results revealed a strong up-modulating effect of TiNP on GDF15 expression and secretion in all subtypes of macrophages. In contrast, stabilin-1 expression was significantly suppressed by TiNP. acLDL and MS-1 uptake by macrophages was also significantly suppressed under the treatment with TiNP. Our findings highlight a consistent ex vivo stimulatory effect of TiNP on GDF15 production and inhibitory effect on STAB1 expression and Stabilin-1-mediated endocytosis. Our results suggest an important implication of TiNP on macrophage healing functions.

ORGANISM(S): Homo sapiens

PROVIDER: GSE179543 | GEO | 2022/01/05

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcriptome of liver tissue in 5 week old Stabilin-1 knock-out mice

2016-07-15 | E-GEOD-78752 | biostudies-arrayexpress

Transcriptome of liver tissue in 5 week old Stabilin-1 knock-out mice

2016-07-15 | GSE78752 | GEO

Transcriptome of liver tissue in 2 week old and E17.5 Stabilin-1 knock-out mice

2018-09-14 | GSE114969 | GEO

Transcriptome of Stabilin-1 siRNA transfected human monocytes

Project description:Stabilin-1/CLEVER-1 is a multidomain protein present in lymphatic and vascular endothelial cells and in M2 immunosuppressive macrophages. Stabilin-1 functions in scavenging, endocytosis and leukocyte adhesion to and transmigration through the endothelial cells. We have analyzed the putative functions of Stabilin-1 in blood monocytes and found that in healthy individuals 60-80% of both CD14+CD16- and CD14+C16+ monocytes, but not CD14dimCD16+ monocytes, expressed Stabilin-1 on the surface. Microarray and RNAseq analysis was performed to get more insight into the effect of Stabilin-1 expression on human monocytes transcriptome.

2015-11-30 | GSE63807 | GEO

Gene expression analysis of Stabilin-1 positive human monocytes

Project description:Stabilin-1/CLEVER-1 is a multidomain protein present in lymphatic and vascular endothelial cells and in M2 immunosuppressive macrophages. Stabilin-1 functions in scavenging, endocytosis and leukocyte adhesion to and transmigration through the endothelial cells. We analyzed the putative functions of Stabilin-1 in blood monocytes. We found that in healthy individuals 60-80% of both CD14+CD16- and CD14+C16+ monocytes, but not CD14dimCD16+ monocytes, expressed Stabilin-1 on the surface. Microarray analysis was performed to study these monocytes subtypes in more detail.

2015-11-30 | GSE63519 | GEO

Genome-wide analysis of M1 and M2 polarized macrophages with CNI-1493 treatment

Project description:Analysis of the effects of CNI-1493 treatment on M1 and M2 polarized macrophages. The purpose of this microarray is to identify genes that may be differentially expressed in M1 or M2 macrophages after treatment with CNI-1493. CNI-1493 is a known inhibitor of M1 macrophages but details of its molecular mechanism are unknown. The effect of CNI-1493 on M2 macrophages has yet to be explored, but we hypothesize that CNI-1493 treatment will attenuate pro-tumor properties of M2 macrophages. We demonstrate with this array that known macrophage markers are unchanged after treatment with CNI-1493, indicating that CNI-1493 does not change the macrophage phenotype on a transcriptional level. Additionally, no candidate genes to suggest how CNI-1493 may attenuate the pro-tumor effects of M2 macrophages are readily identifiable. Total RNA extracted from M1 or M2 macrophages after polarization with GM-CSF (25ng/ml) or M-CSF (25ng/ml) for 7 days, followed by addition of IFN-γ (20ng/ml) and LPS (100ng/ml) or IL-4 (40ng/ml) for 18 hours, respectively, from CD14+ human PBMCs, and treated with CNI-1493 (200nM)

2015-03-12 | E-GEOD-66805 | biostudies-arrayexpress

Effect of hyperglycemia on the transcriptional profile of primary human macrophages

Project description:Hyperglycemia is an essential factor leading to micro- and macrovascular diabetic complications. Macrophages are key innate immune regulators of inflammation that undergo 2 major directions of functional polarization: classically (M1) and alternatively (M2) activated macrophages. The aim of the study was to examine the effect of hyperglycemia on transcriptional activation of M0, M1 and M2 human macrophages.

2017-07-12 | GSE86298 | GEO

The effect of whole-glucan particles on the gene expression of polarized M2 bone-derived macrophages

Project description:Bone-marrow macrophages polarized to M2 phenotype are immunosuppressive. Interestingly, treatment with whole-glucan particles converts M2 macrophages to M1 phenotype with an anti-tumor phenotype. In this study, the effect of WGP treatment for 6 hours on the gene expression of M2 macrophages was assessed.

2015-10-01 | GSE71814 | GEO

Novel transcriptome signatures and markers defining murine macrophages at the extremes of the canonical M1 and M2 polarization spectrum

Project description:Classically (M1) and alternatively activated (M2) macrophages play distinct roles in various physiological and disease processes. Understanding the gene transcription programs that contribute to macrophage polarization along the M1/M2 spectrum may lead to new tools to detect and therapeutically manipulate macrophage phenotype. Here, we define the M1 and M2 macrophage signature through mRNA microarray. The M1 macrophage signature was defined by 629 up-regulated and 732 down-regulated genes while the M2 macrophage signature was formed by 388 up-regulated and 425 down-regulated genes. While a subset of probes was common to both M1 and M2 cells, others were exclusive to each macrophage subset. The common M1/M2 pathways were characterized by changes in various transcriptional regulators and signaling partners, including increases in Kruppel-like Factor (Klf) 4, but decreases in Klf2. To identify M1 and M2 biomarkers that help discriminate these populations, we selected genes that were increased during M1 or M2 differentiation but decreased in the opposite population. Among top novel M1-distinct genes, we identified CD38, G-protein coupled receptor 18 (Gpr18) and Formyl peptide receptor 2 (Fpr2). Among top M2 genes, we found early growth response protein 2 (Egr2) and Myc. We validated these genes by Real-Time PCR and developed a CD38/Egr2-based flow cytometry assay that discriminates between M1 and M2 macrophages. Overall, this work defines the M1 and M2 signature and identifies several novel M1 and M2 genes that may be used to distinguish and manipulate M1 and M2 macrophages. Total RNA was prepared from bone marrow-derived macrophages of wild-type mice (n=2-3 independent mice) treated in M0, M1 or M2 conditions (n=2-3 replicates per condition originating from different mice)

2015-12-08 | E-GEOD-69607 | biostudies-arrayexpress

Genome-wide analysis of M1 and M2 polarized macrophages with CNI-1493 treatment

2015-03-12 | GSE66805 | GEO